Curated News
By: NewsRamp Editorial Staff
July 14, 2025
NanoViricides Advances MPox Treatment with NV-387 Oral Gummies in Phase II Trial
TLDR
- NanoViricides Inc. is nearing finalization of its Phase II trial for NV-387, potentially offering a first-mover advantage in treating MPox and smallpox with a novel oral gummy formulation.
- NanoViricides Inc.'s two-part Phase II trial in the DRC will evaluate NV-387's safety, dosing, and efficacy against MPox Clade Ia and Ib, targeting 80 patients with oral lesions.
- NV-387's development by NanoViricides Inc. could significantly improve global health by providing an effective treatment for MPox and smallpox, reducing suffering and epidemic risks.
- NanoViricides Inc. is testing NV-387 oral gummies for MPox, a creative solution to ease administration for patients with painful oral lesions, marking a potential breakthrough in antiviral therapy.
Impact - Why it Matters
The development of NV-387 by NanoViricides represents a potential breakthrough in the treatment of MPox and other orthopoxvirus infections, addressing a critical gap in current antiviral therapies. With existing treatments showing limited efficacy or adverse effects, NV-387's success could offer a safer, more effective option for patients worldwide, particularly in regions like Africa where MPox remains a significant health threat. This advancement not only highlights the importance of innovative antiviral research but also underscores the global need for accessible and effective treatments against emerging and re-emerging infectious diseases.
Summary
NanoViricides, Inc. (NYSE American: NNVC), a leader in developing broad-spectrum antivirals, is nearing the finalization of its adaptive clinical trial protocol for MPox Clade Ia and Ib, targeting approximately 80 patients in the Democratic Republic of Congo. This two-part Phase II trial aims to evaluate the safety, dosing, and efficacy of NV-387 oral gummies, designed to simplify administration for patients suffering from painful oral lesions. NV-387 stands on the brink of becoming the first drug to demonstrate clinical efficacy against an orthopoxvirus in humans, with potential regulatory approvals sought in Africa, the U.S., and globally, including for smallpox. This development is particularly significant given the limitations of existing treatments like Tecovirimat and Brincidofovir, which have shown poor efficacy or adverse effects in trials. The company also highlights the ongoing threat posed by Clade 1b MPox in Africa and its potential risk to Western nations.
For more details, the full press release can be accessed here. NanoViricides is at the forefront of antiviral therapy, leveraging its nanoviricide(TM) technology to develop treatments for a range of viral infections, including RSV, COVID-19, and influenza, with NV-387 as its lead candidate. The company's innovative approach and strategic partnerships, such as with TheraCour Pharma, Inc., underscore its commitment to addressing unmet medical needs in antiviral treatment.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, NanoViricides Advances MPox Treatment with NV-387 Oral Gummies in Phase II Trial
